In vivo CRISPR screens identify RhoV as a pro-metastasis factor of triple-negative breast cancer

Cancer Sci. 2023 Jun;114(6):2375-2385. doi: 10.1111/cas.15783. Epub 2023 Mar 27.

Abstract

Metastasis is the main death reason for triple-negative breast cancer (TNBC). Thus, identifying the driver genes associated with metastasis of TNBC is urgently needed. CRISPR screens have dramatically enhanced genome editing and made it possible to identify genes associated with metastasis. In this study, we identified and explored the crucial role of ras homolog family member V (RhoV) in TNBC metastasis. Here, we performed customized in vivo CRISPR screens targeting metastasis-related genes obtained from transcriptome analysis of TNBC. The regulatory role of RhoV in TNBC was validated using gain- or loss-of-function studies in vitro and in vivo. We further conducted immunoprecipitation and LC-MS/MS to explore the metastasis mechanism of RhoV. In vivo functional screens identified RhoV as a candidate regulator involved in tumor metastasis. RhoV was frequently upregulated in TNBC and correlated with poor survival. Knockdown of RhoV significantly suppressed cell invasion, migration, and metastasis both in vitro and in vivo. In addition, we provided evidence that p-EGFR interacted with RhoV to activate the downstream signal pathway of RhoV, thereby promoting tumor metastasis. We further confirmed that this association was dependent on GRB2 through a specific proline-rich motif in the N-terminus of RhoV. This mechanism of RhoV is unique, as other Rho family proteins lack the proline-rich motif in the N-terminus.

Keywords: CRISPR screen; EGFR; GRB2; RhoV; invasion and metastasis; triple-negative breast cancer.

MeSH terms

  • Cell Line, Tumor
  • Cell Movement / genetics
  • Cell Proliferation
  • Chromatography, Liquid
  • Clustered Regularly Interspaced Short Palindromic Repeats
  • Humans
  • Tandem Mass Spectrometry
  • Triple Negative Breast Neoplasms* / metabolism

Substances

  • RHOV protein, human